Author Interviews, Infections, NEJM, Pediatrics, Vaccine Studies / 02.02.2023
NEJM: Effectiveness of Pediatric Meningococcal B Vaccine
MedicalResearch.com Interview with:
Manuel García Cenoz MD, PhD(more…)
Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain CIBER Epidemiología y Salud Pública, Madrid
MedicalResearch.com: What is the background for this study?
Response: Neisseria meningitidis is a major cause of severe disease in infants and children. After the introduction of serogroup C vaccines, serogroup B meningococcus has become the main cause of invasive meningococcal disease in Europe. The multicomponent protein-based meningococcal B vaccine (4CMenB, Bexsero, GSK) was licensed in the European Union in 2013. Its authorization was based on immunogenicity studies. Although some countries have introduced the 4CMenB vaccine into the publicly-funded infant immunization programs, the low incidence of the disease has limited the conduct of post-commercialization studies of effectiveness. Meningococcal B vaccine began to be used in Spain in children in 2014, recommended by the Spanish Association of Pediatrics, and paid by their families as it was not publicly-funded. We have conducted a nationwide study including all confirmed cases of invasive meningococcal disease in Spain between October 2015 and September 2019 in children aged two months to five years.